<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630110</url>
  </required_header>
  <id_info>
    <org_study_id>NPI-2358-101</org_study_id>
    <nct_id>NCT00630110</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nereus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nereus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with
      docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new
      blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting
      agents are intended to target the differences between these tumor blood vessels and the blood
      vessels in normal tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with
      docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new
      blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting
      agents are intended to target the differences between these tumor blood vessels and the blood
      vessels in normal tissues. There are indications of advantages in combining vascular
      disrupting agents with standard agents in the treatment of advanced non-small cell lung
      cancer (NSCLC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare overall survival of patients treated with docetaxel to patients treated with docetaxel + NPI-2358</measure>
    <time_frame>Continuous</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare response rate, duration of response, 6-month survival, progression free survival and safety.</measure>
    <time_frame>Continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Continuous</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel (75 mg/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPI-2358 + docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel (75 mg/m2)</description>
    <arm_group_label>docetaxel</arm_group_label>
    <other_name>docetaxel (Taxotere)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPI-2358 + docetaxel</intervention_name>
    <description>NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)</description>
    <arm_group_label>NPI-2358 + docetaxel</arm_group_label>
    <other_name>NPI-2358; docetaxel (Taxotere)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females ≥ 18 years of age

          -  ECOG performance status ≤ 1

          -  Pathologically or histologically confirmed advanced non-small cell lung cancer
             (unresectable Stage IIIb or IV) that has progressed after treatment with at least one
             chemotherapy regimen; measurable disease is not required for enrollment into this
             trial

          -  All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have
             resolved to Grade ≤ 2

          -  Signed informed consent

        Exclusion Criteria:

          -  Administration of certain chemotherapy, biological, immunotherapy, radiation therapy,
             surgery or investigational agent within specified time frames

          -  Significant cardiac history

          -  Prior treatment with tumor vascular disruptive agents

          -  Seizure disorder

          -  Brain metastases

          -  Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy

          -  Known infection with human immunodeficiency virus (HIV), or active hepatitis A, B, or
             C

          -  Patients with a prior hypersensitivity reaction to product components

          -  Pregnant or breast-feeding women.

          -  Concurrent, active second malignancy for which the patient is receiving therapy,
             excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix

          -  Unwilling or unable to comply with procedures required in this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew A Spear, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Nereus Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Pacific Oncology &amp; Hematology Associates</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Texas Health Science Center at San Antonio (CTRC)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinica Privada Instituto de Medicina Nuclear</name>
      <address>
        <city>Bahia Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oncologico De Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>5000 CRD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria Privada Reina Fabiola</name>
      <address>
        <city>Cordoba</city>
        <zip>5000CRD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caici Centro de Asistencia e Investigacion Clinica Integral</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Centrenario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Adult Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bendigo Health Care Group</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacap Pip XII Hospital do Cancer de Barretos</name>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner Liga do Combate as Cancer</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associacao Hospital de Caridade Ijui</name>
      <address>
        <city>Ijui</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas</name>
      <address>
        <city>Porte Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinionco-Clinica de Oncologia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp.das Clinicas da Univ.de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer Aenaldo Vieira de Carvahlo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional del Cancer Oncology</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Van Buren</name>
      <address>
        <city>Valparaiso</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chittaranjan National Cancer Institute</name>
      <address>
        <city>Kolkata</city>
        <state>W. Bengal</state>
        <zip>700026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidwai Memorial Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospital</name>
      <address>
        <city>Chennai</city>
        <zip>600035</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEAROC Cancer Centre S.K. Soni Hospital</name>
      <address>
        <city>Jaipur</city>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Subodh Mitra Cancer Hospital &amp; Research Centre</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andhra Medical College</name>
      <address>
        <city>Vishakhapatnam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>August 15, 2011</last_update_submitted>
  <last_update_submitted_qc>August 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kristine C. Federico, RN BSN - Director Clinical Development</name_title>
    <organization>Nereus Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Non Small Cell Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Diketopiperazines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

